WuXi PharmaTech welcomes Felix Hsu as SVP of U.S. operations
SHANGHAI WuXi PharmaTech, a leading pharmaceutical, biotechnology and medical device research and development outsourcing company with operations in China and the United States, announced Felix Hsu has been appointed to SVP of the company’s U.S. operations.
Prior to joining WuXi, Hsu spent 14 years with Medtronic where he had broad experience as a product manager and business leader. Hsu also served in product management, sales management and strategic planning roles at Abbott Laboratories and as a business manager at Sabratek.
In his new role, Hsu will be responsible for WuXi’s U.S. business. A significant portion of U.S. revenues are derived from serving the medical device industry, where Hsu has extensive experience.
“I am very pleased to welcome Felix on board as we continue to strengthen our U.S. management team,” commented Ge Li, chairman and CEO of WuXi. “Our U.S. operations offer a range of testing services critical to the successful development and regulatory approval of new biologics and medical devices. We expect our U.S. business will grow under Felix’s leadership.”
NAMI releases PSA initiative regarding psychological disorders
ARLINGTON, Va. A nonprofit organization hopes that a new series of public service announcements it has released will encourage people to connect with each other to help themselves, their families and friends who live with psychological disorders.
The National Alliance on Mental Illness announced this week that it had released a PSA initiative called “Puzzle Pieces” that includes four 60-second and three 30-second radio PSAs featuring testimonials from individuals and families that describe their experiences with mental illnesses and the role NAMI played in their recovery.
“We know that with early detection, appropriate treatment and support from family and friends, people with mental illness can lead healthy, rewarding lives,” NAMI executive director Michael Fitzpatrick said. “NAMI members connect to educate each other and encourage their loved ones during their personal journeys to wellness.”
The organization said that an estimated 1-in-5 American families is affected by mental illnesses, including major depression, bipolar disorder, schizophrenia and post-traumatic stress disorder.
KV Pharmaceutical, Gedeon Richter announce licensing agreement
BUDAPEST, Hungary An American drug maker has signed a licensing agreement with a Hungarian pharmaceutical company.
KV Pharmaceutical Co. announced that it had entered into an agreement with Budapest, Hungary-based Gedeon Richter and its American subsidiary for licensing rights to KV technologies and products in the women’s health category.
Under the agreement, Gedeon Richter will have the right to manufacture and distribute certain proprietary technologies and products from KV in the European Union and other areas where it does business, while KV will receive undisclosed milestones and royalties for products that the two companies develop. KV will retain U.S. rights.
“KV Pharmaceutical and Gedeon Richter have for many years enjoyed an excellent relationship and business collaboration, and we are very pleased to extend it in this fashion,” KV Pharmaceutical Co. interim CEO David Van Vliet stated. “We believe this agreement allows both Richter and KV to offer additional enhanced products to more completely serve physicians and their patients.”